Company news
Opus Genetics, Inc. (NASDAQ:IRD) news
Every Opus Genetics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting wit...
September 9, 2026
Opus Genetics Announces Financial Results for Second Quarter 2026 and Provides Corporate Update
August 6, 2026
Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease
August 3, 2026
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
July 9, 2026
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
July 6, 2026
Opus Genetics Added to the Russell 3000, Russell 2000 and Russell Microcap Indexes
June 29, 2026
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
June 26, 2026
Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
June 2, 2026
Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 28, 2026
Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference
May 27, 2026
Opus Genetics to Present at the RBC Capital Markets 2026 Global Healthcare Conference
May 13, 2026
Opus Genetics Announces Financial Results for First Quarter 2026 and Provides Corporate Update
May 12, 2026
Opus Genetics Completes Enrollment in Cohort 1 of Phase 1/2 OPGx-BEST1 Gene Therapy Study
May 7, 2026
Opus Genetics Announces FDA Acceptance of OPGx-LCA5 into Rare Disease Evidence Principles (RDEP) Program
May 4, 2026
Opus Genetics to Participate in Leading Medical Conferences in May 2026
April 27, 2026
Opus Genetics Announces Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
April 10, 2026
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financin...
April 6, 2026
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
March 24, 2026
Opus Genetics Announces Financial Results for Full Year 2025 and Provides Corporate Update
March 10, 2026
Opus Genetics to Present at Upcoming Investor Conferences in March 2026
March 3, 2026
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
February 27, 2026
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment ...
February 25, 2026
Opus Genetics Announces $25 Million Private Placement
February 13, 2026
Opus Genetics to Participate in Upcoming Medical and Industry Conferences in February 2026
February 2, 2026
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
January 27, 2026
Senti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare Conference
January 9, 2026
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts
January 8, 2026
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
December 16, 2025
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
December 11, 2025
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
December 9, 2025
Opus Genetics to Participate in Upcoming Investment Conferences
November 20, 2025
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
November 13, 2025
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
November 12, 2025
Opus Genetics Announces $23 Million Registered Direct Offering
November 6, 2025
Opus Genetics Announces Successful FDA Meeting Supporting Advancement of OPGx-LCA5 Toward Pivotal Trial for LCA5-Related Inherited Retina...
November 6, 2025
Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness
November 3, 2025
Opus Genetics to Participate in Chardan's 9th Annual Genetic Medicines Conference
October 14, 2025
Opus Genetics to Present at Upcoming Medical and Industry Conferences in October 2025
October 2, 2025
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5)
September 30, 2025
Opus Genetics Doses First Patient in Pivotal LYNX-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75% in Keratorefractive P...
September 4, 2025
Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
September 3, 2025
Opus Genetics Appoints Rob Gagnon as Chief Financial Officer
September 2, 2025
Opus Genetics Inherited Retinal Disease Programs Featured at Medical and Industry Conferences in September
August 27, 2025
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate OPGx-BEST1
August 18, 2025
Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update
August 13, 2025
Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 5, 2025
Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness
July 23, 2025
Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 3, 2025
Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Pre...
June 26, 2025
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
June 23, 2025